for eMaxHealthKorean regulatory agency has granted marketing approval for Pharmaxis' asthma management product, Aridol.
"This is the first Asian approval of Aridol," said Pharmaxis Chief Executive Officer Dr Alan Robertson. "Korea is an important base from which to launch and grow Aridol in Asia. There are an estimated 2.5 million asthma sufferers and yet only 160,000 bronchial challenge tests are performed annually to assist with asthma diagnosis and management. The existing broad acceptance of lung function challenge tests presents a firm opportunity for marketing Aridol."
Approval by the Korean regulatory agency was based on the Australian approval and was completed efficiently in just six months.
The Korean pharmaceutical market is one of the twenty largest in the world and together with its Korean distributor BL&H Co Ltd, Pharmaxis will now commence pre-marketing while seeking reimbursement approval through the national health scheme.
The approval process is expected to conclude in the third quarter of 2008.
A simple to use airways inflammation test, Aridol is administered as a dry powder in a hand held inhaler. Doctors can use the results of this test to identify airway hyper-responsiveness -- a hallmark of asthma.
eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
